Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finland Sees Progress On Biosimilar Substitution Plans

Updated Proposals Reflect Industry Criticism; Parliamentary Approval Expected In Weeks

Executive Summary

Updated plans to implement pharmacy-level biosimilar substitution in Finland have been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.

You may also be interested in...



EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe

The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.

Stakeholders Surprised As French Biosimilar Substitution Changes Tack

The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.

Sandoz Completes Coherus Biosimilar Acquisition

Sandoz has closed its deal to acquire the Cimerli US ranibizumab biosimilar business from Coherus “ahead of anticipated timelines.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel